سعر ميمانتكير 10مجم 20 اقراص 2024

Memantine hydrochloride 10 mg scored film-coated tablets, 20 tablets (2 strips), manufactured by Misr for Pharmacare, Egypt; used for Alzheimer's-type dementia.

• Treatment of moderate to severe dementia of the Alzheimer's type.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (at least 5% and more than placebo): dizziness, headache, confusion and constipation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to memantine hydrochloride or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Conditions that raise urine pH (e.g., drastic dietary changes to vegetarian diet, renal tubular acidosis, severe urinary tract infection) may reduce memantine elimination and increase plasma levels.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Seizures have been reported; use caution in patients with a history of seizures.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Other NMDA antagonists (amantadine, ketamine, dextromethorphan)Combined use has not been systematically evaluated; use with caution.DailyMed (U.S. National Library of Medicine)
• Drugs that make the urine alkaline (e.g., carbonic anhydrase inhibitors, sodium bicarbonate)May reduce memantine clearance and increase plasma levels.DailyMed (U.S. National Library of Medicine)

• There are no adequate data on the developmental risk of memantine in pregnant women; animal studies showed adverse developmental effects at doses at or above those used clinically.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• There are no data on the presence of memantine in human or animal milk, or its effects on the breastfed infant or milk production.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Memantine: Postulated to act as a low-to-moderate affinity uncompetitive (open-channel) NMDA receptor antagonist, reducing effects of persistent glutamatergic activation; no evidence that it prevents or slows neurodegeneration (US label).